Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriatic Arthritis AND Arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    225 result(s) found for: Psoriatic Arthritis AND Arthritis. Displaying page 4 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-000242-30 Sponsor Protocol Number: CNTO148PSA3001 Start Date*: 2014-12-29
    Sponsor Name:Janssen Biologics, BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis
    Medical condition: Psoriatic Arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000699-32 Sponsor Protocol Number: EU-0208/REMICADEPSO1006 Start Date*: 2011-09-28
    Sponsor Name:UZ KULeuven, service of Rheumatology
    Full Title: Nail involvement in psoriatic arthritis: a cross-sectional and observational prospective study.
    Medical condition: psoriatic artritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004241-15 Sponsor Protocol Number: IM101-158 Start Date*: 2007-12-21
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis. A...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) NL (Completed) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2014-002056-40 Sponsor Protocol Number: DIA2014-1 Start Date*: 2014-08-12
    Sponsor Name:Diakonhjemmet Hospital AS
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVAT...
    Medical condition: Rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    18.0 100000004858 10071117 Plaque psoriasis LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    18.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    18.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2020-004284-98 Sponsor Protocol Number: CAIN457A02001B Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
    Medical condition: Psoriatic Arthritis, Ankylosing Spondylitis, non-radiographic axial spondyloarthritis, Severe Chronic Plaque Psoriasis, moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076297 Non-radiographic axial spondyloarthritis LLT
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004241-16 Sponsor Protocol Number: B7931030 Start Date*: 2019-08-02
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORI...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) BG (Completed) LT (Completed) EE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002394-38 Sponsor Protocol Number: CAIN457F2354 Start Date*: 2016-05-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) ES (Completed) HU (Completed) BE (Completed) NO (Completed) FR (Completed) AT (Completed) NL (Completed) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001368-46 Sponsor Protocol Number: A3921125 Start Date*: 2013-10-23
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONS...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001163-37 Sponsor Protocol Number: CNTO1959PSA3001 Start Date*: 2017-07-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis i...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005099-36 Sponsor Protocol Number: IM011-055 Start Date*: 2021-08-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: POETYK PsA-2 (055) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Participants with Active Psoriatic Arthritis (Ps...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Completed) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004887-39 Sponsor Protocol Number: SB5-G21-RA Start Date*: 2015-08-08
    Sponsor Name:Samsung Bioepis Co., Ltd
    Full Title: An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis
    Medical condition: Subjects with Rheumatoid Arthritis. The intended use of SB5 is rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), adult Crohn's disease (CD), paediatric CD, ankylosing sp...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000681-10 Sponsor Protocol Number: I1F-MC-RHCG Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes ...
    Medical condition: Juvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002004-39 Sponsor Protocol Number: BAT-2506-002-CR Start Date*: 2021-04-23
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Efficacy and Safety of BAT2506 Versus Simponi® in Participants with Active Psoriatic Arthritis
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003933-14 Sponsor Protocol Number: GLPG0634-CL-227 Start Date*: 2019-05-27
    Sponsor Name:Galapagos NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin...
    Medical condition: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076297 Non-radiographic axial spondyloarthritis LLT
    Population Age: Adults Gender: Male
    Trial protocol: LV (Completed) EE (Completed) BG (Completed) BE (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001970-41 Sponsor Protocol Number: 20170508 Start Date*: 2017-12-21
    Sponsor Name:MD, PhD Salome Kristensen
    Full Title: Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months randomised, open label, par...
    Medical condition: Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10040107 Seropositive rheumatoid arthritis LLT
    23.1 100000004859 10062719 Seronegative rheumatoid arthritis LLT
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    20.0 100000004859 10076297 Non-radiographic axial spondyloarthritis LLT
    21.1 100000004859 10041672 Spondylitis ankylosing LLT
    20.0 100000004859 10002557 Ankylosing spondylitis and other inflammatory spondylopathies LLT
    21.0 100000004859 10045966 Unspecified inflammatory spondylopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001085-42 Sponsor Protocol Number: POISE Start Date*: 2018-06-18
    Sponsor Name:University of Oxford
    Full Title: Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: a 2 arm parallel group feasibility study.
    Medical condition: Psoriatic Arthritis (PsA) is an inflammatory arthritis. PsA is a highly heterogenous disease with a proportion of participants having mild non-progressive disease. Well validated prognostic factor...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002465-22 Sponsor Protocol Number: M16-011 Start Date*: 2018-12-11
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Leas...
    Medical condition: Psoriatic Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Trial now transitioned) NL (Ongoing) LT (Trial now transitioned) PT (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SI (Completed) SK (Trial now transitioned) HR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000847-62 Sponsor Protocol Number: ATI-450-PsA-201 Start Date*: 2022-10-17
    Sponsor Name:Aclaris Therapeutics, Inc.
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients with ...
    Medical condition: Moderate-to-Severe Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000955-11 Sponsor Protocol Number: TILD-19-07 Start Date*: 2021-04-23
    Sponsor Name:Sun Pharmaceutical industries Ltd
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) EE (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002628-27 Sponsor Protocol Number: CAIN457A2206 Start Date*: 2009-01-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-center, proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis
    Medical condition: Psoriatic arthritis (PsA), which belongs to seronegative spondyloarthropathies (SpA).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 04:53:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA